AI ASSISTANT

Ask DrugCentral

Explore drug properties, targets, and indications with answers grounded in DrugCentral.

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

AI can make mistakes. Verify answers against the original sources before relying on them.

Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	1752	60-99-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: methotrimeprazine hirnamin levomeprazine levomepromazin levopromazine levoprome levopromethazine levotomin mepromazine levomepromazine levomepromazine maleate methotrimeprazine hydrochloride nozinan	A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) Molecular weight: 328.47 Formula: C19H24N2OS CLOGP: 5.03 LIPINSKI: 1 HAC: 3 HDO: 0 TPSA: 15.71 ALOGS: -4.80 ROTB: 5 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

methotrimeprazine
hirnamin
levomeprazine
levomepromazin
levopromazine
levoprome
levopromethazine
levotomin
mepromazine
levomepromazine
levomepromazine maleate
methotrimeprazine hydrochloride
nozinan

A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)

Molecular weight: 328.47
Formula: C19H24N2OS
CLOGP: 5.03
LIPINSKI: 1
HAC: 3
HDO: 0
TPSA: 15.71
ALOGS: -4.80
ROTB: 5

Status: OFM

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.30	g	O
0.10	g	P

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	50 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	12 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	9.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	30 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	3.128		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.468		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	28.379	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	97.275	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	3.510	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	10.670	%	High	1
herg	hERG pIC50	5.999	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	15.417	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	29.648	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	4.510	%	High	1
kinase-safety-class	ACVR2B,AKT1,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MET,MTOR,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TTK	40
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	0.374		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	186.638		High	1
mppb	Mouse plasma protein binding (% unbound)	5.180		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	2.109		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	15.790	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	237.137	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	33.180	%	High	1
rppb	Rat plasma protein binding (% unbound)	5.060	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	318.420	uM	High	1

Approvals:

Date	Agency	Company	Orphan
None	FDA	IMMUNEX

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intentional overdose	308.47	24.49	162	9001	93672	90525612
Suicide attempt	284.85	24.49	143	9020	75256	90544028
Toxicity to various agents	235.92	24.49	210	8953	287636	90331648
Somnolence	232.39	24.49	182	8981	208902	90410382
Drug interaction	199.69	24.49	188	8975	276265	90343019
Electrocardiogram QT prolonged	187.79	24.49	107	9056	72349	90546935
Intentional self-injury	186.88	24.49	80	9083	29254	90590030
Suicidal ideation	183.21	24.49	106	9057	73749	90545535
Extrapyramidal disorder	143.24	24.49	56	9107	16247	90603037
Altered state of consciousness	128.36	24.49	63	9100	31469	90587815
Excessive eye blinking	99.85	24.49	24	9139	1348	90617936
Sopor	93.65	24.49	47	9116	24597	90594687
Urinary retention	93.04	24.49	54	9109	37690	90581594
Drug abuse	91.88	24.49	72	9091	82275	90537009
Neuroleptic malignant syndrome	82.55	24.49	37	9126	15059	90604225
Poisoning deliberate	82.55	24.49	38	9125	16448	90602836
Depressed level of consciousness	81.97	24.49	64	9099	72720	90546564
Coma	77.77	24.49	62	9101	72570	90546714
Overdose	66.83	24.49	81	9082	157628	90461656
Pneumonia aspiration	57.23	24.49	41	9122	40899	90578385
Hypotension	52.39	24.49	107	9056	325290	90293994
Aggression	49.91	24.49	32	9131	26636	90592648
Biliary tract infection	47.45	24.49	12	9151	832	90618452
Mental disorder	46.63	24.49	33	9130	32285	90586999
Cholangitis infective	43.65	24.49	10	9153	455	90618829
Flat affect	43.34	24.49	13	9150	1698	90617586
Agitation	43.26	24.49	43	9120	67055	90552229
Seizure	42.60	24.49	64	9099	152565	90466719
Hyperprolactinaemia	41.91	24.49	17	9146	5416	90613868
Cholinergic rebound syndrome	41.14	24.49	6	9157	17	90619267
Hallucination, auditory	39.73	24.49	23	9140	15952	90603332
Salivary hypersecretion	39.48	24.49	19	9144	9073	90610211
Depressed mood	37.69	24.49	35	9128	50187	90569097
Withdrawal syndrome	37.20	24.49	25	9138	22499	90596785
Tension	37.16	24.49	14	9149	3668	90615616
Joint swelling	36.83	24.49	4	9159	503296	90115988
Bacillus infection	36.46	24.49	10	9153	949	90618335
Asphyxia	34.39	24.49	16	9147	7087	90612197
Psychomotor retardation	33.60	24.49	14	9149	4775	90614509
Pulmonary embolism	32.50	24.49	52	9111	130768	90488516
Hypothermia	32.43	24.49	20	9143	15555	90603729
Intestinal obstruction	32.05	24.49	28	9135	37103	90582181
Vascular pain	31.85	24.49	9	9154	953	90618331
Adverse drug reaction	31.22	24.49	48	9115	116653	90502631
Galactorrhoea	30.58	24.49	13	9150	4659	90614625
Hyponatraemia	30.36	24.49	51	9112	133487	90485797
Akathisia	30.26	24.49	17	9146	11142	90608142
Antipsychotic drug level increased	29.75	24.49	12	9151	3767	90615517
Illusion	29.42	24.49	9	9154	1255	90618029
Diabetic hyperosmolar coma	29.19	24.49	7	9156	389	90618895
Bradykinesia	28.91	24.49	14	9149	6774	90612510
Psychiatric symptom	28.28	24.49	14	9149	7104	90612180
Megacolon	28.22	24.49	10	9153	2204	90617080
Behaviour disorder	27.39	24.49	12	9151	4623	90614661
Neutropenic sepsis	27.28	24.49	19	9144	18111	90601173
Blood prolactin increased	26.76	24.49	11	9152	3626	90615658
Tonic clonic movements	26.69	24.49	9	9154	1713	90617571
Disinhibition	26.55	24.49	8	9155	1060	90618224
Blood phosphorus decreased	26.44	24.49	12	9151	5022	90614262
Disturbance in attention	26.39	24.49	28	9135	47081	90572203
Product use in unapproved indication	26.12	24.49	84	9079	336152	90283132
Blood creatine phosphokinase increased	26.09	24.49	24	9139	33999	90585285
Metabolic syndrome	25.90	24.49	9	9154	1873	90617411
Sedation	25.87	24.49	28	9135	48143	90571141
Schizophrenia	25.70	24.49	17	9146	14897	90604387
Constipation	25.46	24.49	74	9089	280321	90338963
Perforation	25.39	24.49	9	9154	1985	90617299
Pain	24.94	24.49	39	9124	996302	89622982
Pruritus	24.64	24.49	12	9151	541513	90077771

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neuroleptic malignant syndrome	191.81	23.94	91	8414	21381	42591449
Drug abuse	187.67	23.94	160	8345	104611	42508219
Dystonic tremor	132.98	23.94	27	8478	336	42612494
Dystonia	107.44	23.94	52	8453	12738	42600092
Extrapyramidal disorder	106.43	23.94	56	8449	16356	42596474
Suicide attempt	102.53	23.94	80	8425	46020	42566810
Drug interaction	99.60	23.94	185	8320	266814	42346016
Intentional self-injury	98.93	23.94	52	8453	15150	42597680
Altered state of consciousness	95.28	23.94	64	8441	29195	42583635
Toxicity to various agents	85.65	23.94	159	8346	228977	42383853
Somnolence	75.42	23.94	115	8390	140990	42471840
Restlessness	74.35	23.94	55	8450	29194	42583636
Sopor	74.26	23.94	41	8464	13161	42599669
Miosis	73.56	23.94	41	8464	13405	42599425
Intentional overdose	72.92	23.94	69	8436	51387	42561443
Intestinal haemorrhage	65.72	23.94	26	8479	3925	42608905
Blood glucose fluctuation	65.33	23.94	27	8478	4560	42608270
Acute pulmonary oedema	63.21	23.94	32	8473	8619	42604211
Poisoning	62.34	23.94	38	8467	14661	42598169
Aggression	62.14	23.94	59	8446	44104	42568726
Electrocardiogram QT prolonged	61.73	23.94	61	8444	47884	42564946
Psychomotor hyperactivity	58.81	23.94	33	8472	10925	42601905
Blood creatine phosphokinase increased	55.83	23.94	58	8447	48280	42564550
Asphyxia	55.63	23.94	29	8476	8297	42604533
Sedation	55.29	23.94	47	8458	30428	42582402
Blood glucose abnormal	51.27	23.94	26	8479	7027	42605803
Sudden death	50.83	23.94	35	8470	16594	42596236
Wrong patient received product	50.72	23.94	21	8484	3562	42609268
Coma	49.24	23.94	57	8448	53497	42559333
Cognitive disorder	48.72	23.94	46	8459	34126	42578704
Schizophrenia	44.03	23.94	27	8478	10523	42602307
Dyspnoea	43.61	23.94	17	8488	442604	42170226
Parkinsonism	41.33	23.94	26	8479	10597	42602233
Depressed level of consciousness	40.68	23.94	49	8456	47921	42564909
Urinary retention	40.60	23.94	46	8459	42168	42570662
Urinary incontinence	40.49	23.94	34	8471	21634	42591196
Feelings of worthlessness	40.48	23.94	10	8495	314	42612516
Abulia	37.33	23.94	11	8494	679	42612151
Muscle contracture	36.90	23.94	13	8492	1422	42611408
Akathisia	36.75	23.94	24	8481	10427	42602403
Gastrointestinal hypermotility	36.23	23.94	8	8497	152	42612678
Electrocardiogram QT shortened	35.98	23.94	8	8497	157	42612673
Salivary hypersecretion	35.74	23.94	24	8481	10919	42601911
Rhabdomyolysis	35.29	23.94	59	8446	77960	42534870
Confusional state	34.74	23.94	92	8413	167505	42445325
Self-destructive behaviour	33.95	23.94	9	8496	376	42612454
Therapeutic product effect incomplete	32.55	23.94	54	8451	70885	42541945
Hyperprolactinaemia	31.94	23.94	13	8492	2110	42610720
Drug screen false positive	30.36	23.94	10	8495	892	42611938
Victim of chemical submission	30.34	23.94	7	8498	163	42612667
Arthralgia	30.20	23.94	3	8502	205235	42407595
Wrong schedule	30.12	23.94	8	8497	337	42612493
Tachycardia	29.03	23.94	63	8442	101024	42511806
Restless legs syndrome	28.82	23.94	20	8485	9594	42603236
Product administration error	28.66	23.94	26	8479	18317	42594513
Substance use disorder	28.41	23.94	16	8489	5329	42607501
Rash	28.29	23.94	10	8495	276944	42335886
Mumps	28.02	23.94	6	8499	98	42612732
Poisoning deliberate	27.87	23.94	20	8485	10114	42602716
Contraindicated product administered	26.81	23.94	29	8476	25243	42587587
Diarrhoea	26.39	23.94	32	8473	460817	42152013
Overdose	26.21	23.94	62	8443	105202	42507628
Balance disorder	25.61	23.94	39	8466	47606	42565224
Psychotic disorder	25.02	23.94	30	8475	29178	42583652
Obsessive-compulsive disorder	24.97	23.94	16	8489	6727	42606103
Electrocardiogram QRS complex prolonged	24.54	23.94	15	8490	5808	42607022
Hyperhidrosis	24.39	23.94	55	8450	90457	42522373
Haematoma	24.36	23.94	29	8476	27994	42584836
Respiratory depression	24.24	23.94	24	8481	18844	42593986
Hallucination	24.02	23.94	42	8463	57465	42555365

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Suicide attempt	357.03	21.26	212	16550	103182	110469355
Neuroleptic malignant syndrome	278.96	21.26	125	16637	33934	110538603
Somnolence	278.09	21.26	280	16482	297169	110275368
Intentional overdose	266.98	21.26	194	16568	132307	110440230
Drug abuse	253.66	21.26	212	16550	177199	110395338
Toxicity to various agents	238.85	21.26	327	16435	480228	110092309
Drug interaction	228.69	21.26	327	16435	499856	110072681
Altered state of consciousness	206.16	21.26	121	16641	57505	110515032
Extrapyramidal disorder	205.11	21.26	96	16666	28771	110543766
Electrocardiogram QT prolonged	195.79	21.26	149	16613	108811	110463726
Intentional self-injury	190.01	21.26	99	16663	37330	110535207
Sopor	158.34	21.26	87	16675	36459	110536078
Suicidal ideation	154.65	21.26	122	16640	93815	110478722
Dystonic tremor	145.52	21.26	28	16734	349	110572188
Coma	124.83	21.26	119	16643	117750	110454787
Urinary retention	111.44	21.26	89	16673	69594	110502943
Dystonia	110.58	21.26	61	16701	25744	110546793
Aggression	106.34	21.26	81	16681	59129	110513408
Depressed level of consciousness	105.15	21.26	106	16656	112172	110460365
Blood creatine phosphokinase increased	93.38	21.26	82	16680	72995	110499542
Poisoning deliberate	93.35	21.26	55	16707	26276	110546261
Restlessness	81.82	21.26	68	16694	56191	110516346
Psychomotor hyperactivity	78.90	21.26	45	16717	20232	110552305
Overdose	78.63	21.26	133	16629	233661	110338876
Pneumonia aspiration	74.76	21.26	76	16686	81157	110491380
Salivary hypersecretion	74.13	21.26	41	16721	17380	110555157
Excessive eye blinking	69.71	21.26	21	16741	1849	110570688
Akathisia	69.34	21.26	39	16723	17074	110555463
Miosis	67.81	21.26	42	16720	21941	110550596
Wrong patient received product	66.01	21.26	28	16734	6646	110565891
Sedation	63.76	21.26	65	16697	69618	110502919
Sudden death	61.38	21.26	41	16721	24354	110548183
Asphyxia	59.24	21.26	33	16729	14182	110558355
Poisoning	57.10	21.26	42	16720	29063	110543474
Agitation	54.45	21.26	76	16686	112975	110459562
Psychiatric symptom	54.39	21.26	27	16735	9186	110563351
Tachycardia	53.72	21.26	111	16651	226534	110346003
Drug hypersensitivity	53.57	21.26	4	16758	454086	110118451
Schizophrenia	53.28	21.26	36	16726	21790	110550747
Substance abuse	49.40	21.26	28	16734	12435	110560102
Acute pulmonary oedema	48.72	21.26	31	16731	16965	110555572
Intestinal haemorrhage	47.79	21.26	23	16739	7318	110565219
Hyperprolactinaemia	47.09	21.26	22	16740	6553	110565984
Joint swelling	46.75	21.26	6	16756	442839	110129698
Rhabdomyolysis	46.54	21.26	73	16689	120328	110452209
Depressed mood	45.52	21.26	51	16711	60758	110511779
Adverse drug reaction	45.03	21.26	67	16695	105492	110467045
Pain	42.94	21.26	49	16713	954906	109617631
Hypothermia	42.89	21.26	34	16728	26268	110546269
Ileus paralytic	42.87	21.26	25	16737	11712	110560825
Rash	42.79	21.26	37	16725	820927	109751610
Electrocardiogram QRS complex prolonged	40.47	21.26	25	16737	12996	110559541
Arthralgia	38.40	21.26	37	16725	779595	109792942
Feelings of worthlessness	37.26	21.26	10	16752	580	110571957
Urticaria	37.05	21.26	3	16759	318854	110253683
Muscle rigidity	36.92	21.26	30	16732	24001	110548536
Behaviour disorder	36.43	21.26	21	16741	9626	110562911
Substance use disorder	36.16	21.26	19	16743	7271	110565266
Colitis ischaemic	35.69	21.26	26	16736	17724	110554813
Seizure	35.52	21.26	93	16669	221092	110351445
Intestinal obstruction	35.39	21.26	42	16720	53185	110519352
Blood glucose fluctuation	35.19	21.26	19	16743	7679	110564858
Parkinsonism	34.72	21.26	28	16734	22159	110550378
Biliary tract infection	34.19	21.26	12	16750	1712	110570825
Cholangitis infective	33.78	21.26	10	16752	829	110571708
Cognitive disorder	33.73	21.26	53	16709	87458	110485079
Accidental poisoning	33.41	21.26	13	16749	2474	110570063
Mental disorder	33.34	21.26	35	16727	38756	110533781
Abnormal behaviour	33.16	21.26	35	16727	39004	110533533
Hallucination	33.12	21.26	57	16705	101375	110471162
Pruritus	33.05	21.26	24	16738	581536	109991001
Swelling	32.07	21.26	7	16755	351034	110221503
Cholinergic rebound syndrome	32.04	21.26	6	16756	64	110572473
Mania	32.03	21.26	26	16736	20770	110551767
Muscle contracture	31.88	21.26	13	16749	2795	110569742
Hypersensitivity	31.43	21.26	11	16751	403987	110168550
Blood glucose abnormal	30.80	21.26	21	16741	12895	110559642
Withdrawal syndrome	30.03	21.26	30	16732	31350	110541187
Megacolon	29.58	21.26	14	16748	4291	110568246
Psychomotor retardation	29.53	21.26	17	16745	7775	110564762
Hepatic cytolysis	29.51	21.26	39	16723	55014	110517523
Abulia	29.37	21.26	10	16752	1303	110571234
Sinusitis	29.03	21.26	5	16757	296683	110275854
Cough	29.00	21.26	17	16745	461624	110110913
Drug screen false positive	28.96	21.26	10	16752	1359	110571178
Cardio-respiratory arrest	28.92	21.26	58	16704	115778	110456759
Dyskinesia	28.44	21.26	37	16725	51409	110521128
Alopecia	28.25	21.26	10	16752	364743	110207794
Wrong patient	28.08	21.26	10	16752	1489	110571048
Wheezing	28.05	21.26	3	16759	255227	110317310
Maternal exposure during pregnancy	28.00	21.26	3	16759	254880	110317657
Obsessive-compulsive disorder	27.98	21.26	16	16746	7225	110565312
Choking	27.83	21.26	21	16741	15089	110557448
Stomatitis	27.70	21.26	4	16758	270238	110302299
Tremor	27.47	21.26	80	16682	202152	110370385
Tension	27.39	21.26	14	16748	5064	110567473
Asthma	27.36	21.26	3	16759	250288	110322249
Bacillus infection	27.35	21.26	10	16752	1604	110570933
Respiratory acidosis	27.22	21.26	20	16742	13806	110558731
Galactorrhoea	26.99	21.26	13	16749	4142	110568395
Abdominal discomfort	26.95	21.26	13	16749	393845	110178692
Headache	26.63	21.26	59	16703	882318	109690219
Vascular pain	26.50	21.26	9	16753	1164	110571373
Wrong schedule	26.47	21.26	8	16754	712	110571825
Flat affect	26.41	21.26	11	16751	2494	110570043
Hyponatraemia	25.73	21.26	82	16680	217571	110354966
Drug intolerance	25.49	21.26	15	16747	406497	110166040
Pain in extremity	25.28	21.26	22	16740	487096	110085441
Treatment noncompliance	25.12	21.26	42	16720	72948	110499589
Self-destructive behaviour	25.11	21.26	8	16754	847	110571690
Hallucination, auditory	24.82	21.26	25	16737	26372	110546165
Disturbance in attention	24.52	21.26	38	16724	61957	110510580
Blister	24.17	21.26	3	16759	227373	110345164
Pulmonary embolism	23.72	21.26	79	16683	214395	110358142
Constipation	23.56	21.26	112	16650	357674	110214863
Neuroleptic-induced deficit syndrome	23.54	21.26	4	16758	23	110572514
Mobility decreased	23.23	21.26	4	16758	237418	110335119
Dyspnoea	23.18	21.26	88	16674	1106784	109465753
Obsessive-compulsive symptom	22.79	21.26	6	16756	323	110572214
Perforation	22.69	21.26	9	16753	1801	110570736
Deep vein thrombosis	22.63	21.26	59	16703	139828	110432709
Therapeutic product effect incomplete	22.62	21.26	80	16682	223725	110348812
Hyperhidrosis	22.53	21.26	71	16691	187227	110385310
Discomfort	22.42	21.26	3	16759	214704	110357833
Bradykinesia	22.14	21.26	16	16746	10772	110561765
Blood phosphorus decreased	22.01	21.26	14	16748	7651	110564886
Illusion	21.79	21.26	9	16753	1998	110570539
Tonic clonic movements	21.52	21.26	10	16752	2942	110569595
Product dose omission issue	21.43	21.26	11	16751	321771	110250766
Delusion	21.43	21.26	22	16740	23733	110548804

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral calcification	30.59	26.52	5	12	27	113909

Pharmacologic Action:

Source	Code	Description
ATC	N05AA02	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Phenothiazines with aliphatic side-chain
MeSH PA	D000700	Analgesics
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018492	Dopamine Antagonists
MeSH PA	D018689	Sensory System Agents
MeSH PA	D018712	Analgesics, Non-Narcotic
CHEBI has role	CHEBI:35469	antidepressant
CHEBI has role	CHEBI:35474	anxiolytic drug
CHEBI has role	CHEBI:35476	antipsychotic agent
CHEBI has role	CHEBI:35481	non-narcotic analgesic
CHEBI has role	CHEBI:37930	phenothiazine antipsychotic drug
CHEBI has role	CHEBI:48279	serotonergic antagonist
CHEBI has role	CHEBI:48561	dopaminergic antagonist
CHEBI has role	CHEBI:48873	cholinergic antagonist
CHEBI has role	CHEBI:76779	EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
CHEBI has role	CHEBI:149553	anticoronaviral agent

Related Drugs by ATC class:

N05AA Phenothiazines with aliphatic side-chain 6 drugs

acepromazine chlorproethazine chlorpromazine cyamemazine promazine triflupromazine

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Alcoholism	contraindication	7200002
Organophosphate poisoning	contraindication	8260003
Weight gain finding	contraindication	8943002
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Senile dementia	contraindication	15662003
Chronic disease of respiratory system	contraindication	17097001
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Orthostatic hypotension	contraindication	28651003
Torsades de pointes	contraindication	31722008
Parkinsonism	contraindication	32798002
Conduction disorder of the heart	contraindication	44808001
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Extrapyramidal disease	contraindication	76349003
Hyperglycemia	contraindication	80394007	DOID:4195
Epilepsy	contraindication	84757009	DOID:1826
Leukopenia	contraindication	84828003	DOID:615
Stupor	contraindication	89458003
Tardive dyskinesia	contraindication	102449007
Prolonged QT interval	contraindication	111975006
Acute disease of cardiovascular system	contraindication	128487001
Angina pectoris	contraindication	194828000
Disease of liver	contraindication	235856003	DOID:409
Metabolic syndrome X	contraindication	237602007	DOID:14221
Hyperprolactinemia	contraindication	237662005	DOID:12700
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Anemia	contraindication	271737000	DOID:2355
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Coma	contraindication	371632003
At risk for aspiration	contraindication	371736008
Visual impairment	contraindication	397540003
Breastfeeding (mother)	contraindication	413712001
Myocardial ischemia	contraindication	414795007	DOID:3393
Obesity	contraindication	414916001	DOID:9970
Congenital long QT syndrome	contraindication	442917000
Carcinoma of female breast	contraindication	447782002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.92	Basic
pKa2	4.55	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	9.24		PDSP
Pleiotropic ABC efflux transporter of multiple drugs	Transporter		PDR5_YEAST		IC50	5.02		CHEMBL

External reference:

ID	Source
4018915	VUID
N0000147208	NUI
D00403	KEGG_DRUG
4018915	VANDF
CHEBI:6838	CHEBI
CHEMBL1764	ChEMBL_ID
CHEMBL1725730	ChEMBL_ID
7603	IUPHAR_LIGAND_ID
705	INN_ID
7104-38-3	SECONDARY_CAS_RN
DB01403	DRUGBANK_ID
9G0LAW7ATQ	UNII
160372	RXNORM
1834	MMSL
5078	MMSL
d00814	MMSL
001581	NDDF
004134	NDDF
005070	NDDF
387509007	SNOMEDCT_US
395790003	SNOMEDCT_US
57911003	SNOMEDCT_US
89029005	SNOMEDCT_US
C0025678	UMLSCUI
D008728	MESH_DESCRIPTOR_UI
CHEMBL2104973	ChEMBL_ID
72287	PUBCHEM_CID
C017901	MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

None

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

levomepromazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: